Form 4: Versant Venture Capital Sells Shares in Monte Rosa Therapeutics

Versant Venture Capital VI, L.P. sold 1,132,566 shares of Monte Rosa Therapeutics, Inc. at a weighted average price of $6.5296 on September 20, 2024.

Summary

• Versant Venture Capital VI, L.P. sold 1,132,566 shares of Monte Rosa Therapeutics, Inc. (GLUE) on September 20, 2024.
• The shares were sold at a weighted average price of $6.5296, with individual transaction prices ranging from $6.30 to $6.80.
• Following the transaction, Versant Venture Capital VI, L.P. directly owns 5,099,336 shares.
• Versant Vantage I, L.P. indirectly owns 2,097,938 shares.
• Versant Ventures VI GP, L.P. is the general partner of Versant Venture Capital VI, L.P., and Versant Ventures VI GP-GP, LLC is the general partner of Versant Ventures VI GP, L.P.
• Versant Vantage I GP, L.P. is the general partner of Versant Vantage I, L.P., and Versant Vantage I GP-GP, LLC is the general partner of Versant Vantage I GP, L.P.
• These general partners may be deemed to share voting, investment, and dispositive power over the shares, but disclaim beneficial ownership except to the extent of their pecuniary interests.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative as a major shareholder is reducing their position, which could indicate a lack of confidence or a strategic shift.

Negatives

• Versant Venture Capital, a significant shareholder, has reduced its stake in Monte Rosa Therapeutics.

Risks

• Continued selling pressure from major shareholders could negatively impact the stock price.

Industry Context

Form 4 filings are standard disclosures for insiders selling shares, providing transparency to the market.

Stakeholder Impact

• Shareholders may react to the news of Versant Venture Capital's share sale.
• The market may interpret the sale as a signal about the company's prospects.

Key Dates